- Home
- CLPR vs SER Comparison
CLPR vs SER Comparison
Compare CLPR & SER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLPR | SER |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | United States | United States |
| Employees | 171 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.6M | 42.0M |
| IPO Year | 2017 | 2018 |
Fundamental Metrics
Financial Performance| Metric | CLPR | SER |
|---|---|---|
| Price | $3.50 | $3.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | ★ 61.0K | 15.6K |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | ★ 10.86% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $154,179,000.00 | $116,000.00 |
| Revenue This Year | N/A | $134.46 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 5.90 | N/A |
| 52 Week Low | $3.37 | $3.20 |
| 52 Week High | $6.49 | $7.92 |
Technical Indicators
Market Signals| Indicator | CLPR | SER |
|---|---|---|
| Relative Strength Index (RSI) | 38.85 | 32.60 |
| Support Level | $3.37 | $3.68 |
| Resistance Level | $3.65 | $4.26 |
| Average True Range (ATR) | 0.15 | 0.27 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 23.92 | 9.61 |
Price Performance
Historical ComparisonAbout CLPR Clipper Realty Inc.
Clipper Realty Inc is a self-administered and self-managed real estate company. It acquires, owns, manages, operates, and repositions multifamily residential and commercial properties in the New York metropolitan area, with a portfolio in Manhattan and Brooklyn. It has classified its reporting segments into Residential Rental Properties and Commercial Rental Properties. The company derives its revenue mostly from the Residential segment.
About SER Serina Therapeutics Inc.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The Company has one reportable segment relating to the research and development of its POZ platform.